Oncotarget

Trk and IGF1R-Related Signaling Linked to Delayed Ewing Sarcoma Growth

BUFFALO, NY – August 10, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on August 7, 2026, titled “Delayed growth of SK-ES-1 Ewing sarcoma tumor xenografts is associated with reduced Trk and IGF1R pathway markers.” The study was led by first author Bruna Almeida dos Santos and corresponding author Caroline Brunetto de Farias, primarily affiliated with the Federal University of Rio Grande do Sul and the National Science and Technology Institute for Children’s Cancer Biology and Pediatric Oncology (INCT BioOncoPed), with de Farias also affiliated with the Children’s Cancer Institute (ICI) in Brazil. The research team investigated whether targeting tropomyosin receptor kinase (Trk) and related signaling pathways could interfere with Ewing sarcoma growth. Ewing sarcoma is an aggressive cancer that primarily affects children and adolescents and can arise in bone or soft tissue. Although modern multimodal treatments have substantially improved outcomes for patients with localized disease, the prognosis remains considerably poorer for metastatic or relapsed Ewing sarcoma. This has driven efforts to identify molecular pathways that could provide additional therapeutic targets. One potential target involves the Trk family of receptor tyrosine kinases. TrkA, TrkB, and TrkC are encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively, and regulate intracellular signaling pathways involved in cell survival, differentiation, and growth. Previous work from the research group showed that TrkA and TrkB are expressed in Ewing sarcoma and that blocking these receptors can reduce tumor-cell proliferation. Full press release - https://www.oncotarget.com/news/pr/trk-and-igf1r-related-signaling-linked-to-delayed-ewing-sarcoma-growth/ DOI - https://doi.org/10.18632/oncotarget.28911 Correspondence to - Caroline Brunetto de Farias - cbfarias@zielbiosciences.com Abstract video - https://www.youtube.com/watch?v=ZG-vhYfHjuw Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28911 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Ewing sarcoma, K252a, Trk, NTRK, insulin-like growth factor 1 receptor To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

CTHRC1 in the Tumor Microenvironment Drives Colorectal Cancer Growth in Mouse Study

Colorectal cancer does not develop in isolation. Cancer cells exist within a complex tumor microenvironment made up of fibroblasts, immune cells, blood vessels, and extracellular matrix. Increasing evidence suggests that these surrounding cells and structures can influence whether tumors grow, regress, or evade the immune system. A research paper published in Volume 17 of Oncotarget, titled “Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer,” investigated the role of collagen triple helix repeat containing 1 (CTHRC1), a secreted protein found in cancer-associated stroma. Full blog post - https://www.oncotarget.org/2026/08/10/cthrc1-in-the-tumor-microenvironment-drives-colorectal-cancer-growth-in-mouse-study/ DOI - https://doi.org/10.18632/oncotarget.28878 Correspondence to: Sergey Ryzhov - Sergey.Ryzhov@mainehealth.org; Volkhard Lindner- Volkhard.Lindner@mainehealth.org; Michaela R. Reagan - Michaela.Reagan@mainehealth.org Abstract video - https://www.youtube.com/watch?v=gTbYy6vGd7E Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28878 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Cthrc1, CRC, colorectal cancer, subcutaneous tumor model, immune analysis To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Artificial Intelligence Could Transform Nutrition Care for Cancer Patients

Nutrition plays a critical role in cancer care, yet it is often overlooked. Many patients experience weight loss, muscle wasting, treatment-related side effects, and changes in appetite that can affect their ability to tolerate therapy and maintain quality of life. Although nutrition specialists can help manage these challenges, access to specialized nutritional care remains limited in many healthcare settings. An editorial published in Volume 17 of Oncotarget, titled “Artificial intelligence in nutritional oncology: From isolated screening tools to agentic intervention systems,” explores how advances in artificial intelligence (AI) could help address this gap. The editorial was written by Arnab Sarkar and corresponding author Yashbir Singh-Wolkenhauer, who is affiliated with the Department of Radiology, Mayo Clinic, Rochester, Minnesota. Rather than presenting new clinical trial data, the authors outline a future vision in which AI systems move beyond isolated tasks to continuously support nutritional care throughout a patient’s cancer journey. Full blog post - https://www.oncotarget.org/2026/07/28/artificial-intelligence-could-transform-nutrition-care-for-cancer-patients/ DOI - https://doi.org/10.18632/oncotarget.28874 Correspondence to - Yashbir Singh-Wolkenhauer - singh.yashbir@mayo.edu Abstract video - https://www.youtube.com/watch?v=sVKhRSr5xaY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28874 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, artificial intelligence To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Molecular Tumor Board Explores Personalized Treatment Strategies for Patient with Multiple Cancers

BUFFALO, NY – July 22, 2026 – A new #PrecisionOncology paper was #Published in Volume 17 of Oncotarget on July 21, 2026, titled “WIN-MTB-2024017 – WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.” The study was led by Oncotarget Editor-in-Chief, Dr. Wafik S. El-Deiry, from the Worldwide Innovative Network (WIN) Association – WIN Consortium and Legorreta Cancer Center at Brown University. Patients who develop multiple primary cancers face unique diagnostic and treatment challenges because each tumor may have distinct biological characteristics requiring different therapeutic approaches. Advances in genomic profiling and precision oncology now enable clinicians to better distinguish between independent tumors and recurrent disease while identifying molecular alterations that may guide individualized treatment strategies. This case report demonstrates how an international molecular tumor board integrated comprehensive genomic data with multidisciplinary expertise to develop personalized recommendations for a patient with an exceptionally complex cancer history. The case describes the clinical journey of a 48-year-old woman carrying a germline BRCA1 mutation who developed multiple primary cancers over nearly two decades, including breast cancer, basal cell carcinoma of the skin, high-grade serous ovarian carcinoma, colon cancer, and small bowel adenocarcinoma. During this time, she underwent multiple surgeries, chemotherapy regimens, targeted therapy with the PARP inhibitor niraparib, and extensive molecular testing to characterize each malignancy. Full press release - https://www.oncotarget.com/news/pr/international-molecular-tumor-board-explores-personalized-treatment-strategies-for-a-patient-with-multiple-primary-cancers/ DOI - https://doi.org/10.18632/oncotarget.28899 Correspondence to - Wafik S. El-Deiry - wafik_el-deiry@brown.edu Abstract video - https://www.youtube.com/watch?v=4KIDbmq6ui8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28899 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, precision oncology, molecular tumor board To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Rare Genetic Combination in Gastrointestinal Tumor Offers New Insights Into Precision Cancer Care

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Although many GISTs can be effectively treated with targeted therapies, their response to treatment depends largely on the specific genetic alterations driving tumor growth. Advances in molecular testing have transformed the management of these tumors, allowing clinicians to tailor treatment based on each patient’s genetic profile. A case report published in Volume 17 of Oncotarget, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report,” describes an exceptionally rare case involving a patient whose tumor carried two genetic alterations that are traditionally considered mutually exclusive. Full blog post - https://www.oncotarget.org/2026/07/13/rare-genetic-combination-in-gastrointestinal-tumor-offers-new-insights-into-precision-cancer-care/ DOI - https://doi.org/10.18632/oncotarget.28863 Correspondence to - Joseph G. Crompton - jcrompton@mednet.ucla.edu Abstract video - https://www.youtube.com/watch?v=eB_QG2vBNCE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28863 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, GIST, KIT duplication, SDHC mutation, genetic testing, case report To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM